Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach

Current Pharmaceutical Design

Volumn 14, Issue 13, 2008, Pages 1261-1269

  Sanna, Giovanni ^a   Bertolaccini, Maria Laura ^b   Khamashtra, Munther A ^b  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anticardiolipin; Anticoagulation; Antiphospholipid syndrome; CNS; Immunosuppression; Ischemia; Lupus anticoagulant; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALTEPLASE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; HALOPERIDOL; HEPARIN; ILOPROST; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MANNITOL; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISOLONE; PSYCHOTROPIC AGENT; RISPERIDONE; RITUXIMAB; STEROID; UNINDEXED DRUG; WARFARIN;

ADJUVANT THERAPY; ANTICOAGULATION; ANXIETY DISORDER; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHOREA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; EPILEPSY; HEADACHE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCONTINENCE; LIVER TOXICITY; LOW DRUG DOSE; MIGRAINE; MONOTHERAPY; MOOD DISORDER; MYELITIS; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OVARY INSUFFICIENCY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; REVIEW; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

EID: 47349097789     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208799316401     Document Type: Review

References (114)

1. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Mathieu A, Hughes GR. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-92.
2. Bruyn GA. Controversies in lupus: Nervous system involvement. Ann Rheum Dis 1995; 54: 159-67.
3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
4. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: A population-based evaluation. Arthritis Rheum 2001; 45: 419-23.
5. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL et al. Neuropsychiatric syndromes in in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-20.
6. Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F, et al. Neuropsychiatric lupus syndromes: Relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-10.
7. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: Attribution and clinical significance. J Rheumatol 2004; 31: 2156-62.
8. Senecal JL, Raymond Y. The pathogenesis of neuropsychiatric manifestations in systemic lupus erythematosus: A disease in search of autoantibodies or autoantibodies in search of a disease? J Rheumatol 2004; 31: 2093-8.
9. Hughes GR. The Prosser-White oration 1983. Connective tissue disease and the skin. Clin Exp Dermatol 1984; 9: 535-44.
10. Asherson R, Mercey D, Phillips G, Sheehan N, Gharavi A, Harris E, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: Association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46: 605-11.
11. Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 1989; 86: 391-9.
12. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-65.
13. Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181-9.
14. Bertolaccini ML, Hughes GR, Khamashta MA. Revisiting antiphospholipid antibodies: From targeting phospholipids to phospholipid binding proteins. Clin Lab 2004; 50: 653-65.
15. Khamashta MA, Bertolaccini ML, Hughes GR. Antiphospholipid (Hughes) syndrome. Autoimmunity 2004; 37: 309-12.
16. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
17. Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2000: CD002265.
18. Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1311-20.
19. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dig 2005; 64: 620-5.
20. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: A clinical approach to therapy. Lupus 2003; 12: 935-42.
21. Hung JJ, Ou LS, Lee WI, Huang JL. Central nervous system infections in patients with systemic lupus erthematosus. J Rheumatol 2005; 32: 40-3
22. Warnatz K, Peter HH, Schumacher M, Wiese L, Prasse A, Petschner F, et al. Infectious CNS disease as a differetial diagnosis in systemic rheumatic diseases: Three case reports and a review of the literature. Ann Rheum Dig 2003; 62: 50-7.
23. Khamashta MA, Cervera R, Hughes GR. The central nervous system in systemic lupus erythematosus. Rheumatol Int 1991; 11: 117-9.
24. Tincani A, Brey R, Balestrieri G, Yitali C, Doria A, Galeuzi M, et al. International survey on the management of patients with SLE. II. The results of a questionnaire regarding neuropsychiatric manifestations. Clin Exp Rheumatol 1996; 14(Suppl 16): S23-9.
25. Nishimura K, Omori M, Horikawa N, Tanaka E, Furuya T, Harigai M. Risperidone in the treatment of acute confusional state (delirium) due to neuropsychiatric lupus erythematosus: Case report. Int J Psychiatry Med 2003; 33: 299-303.
26. Moore PM. In: Lahita RG Ed, Systemic lupus erythematosus, San Diego, CA, Academic Press 1999; 575-601.
27. Moore PM, Isenberg D. Therapy of neuro-psychiatric systemic lupus erythematosus. Rheumatol Eur 1997; 26: 36-9.
28. Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99: 397-401.
29. Mok CC, Lau CS, Wong RW. Neutopsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766-71.
30. Alarcon-Segovia D, Estanol B, Garcia-Ramos U, Villa AR. Antiphospholipid antibodies and the antiphospholipid syndrome. Clinical relevance in neuropsychiatric systemic lupus erythematosus. Ann N Y Acad Sci 1997; 823: 279-88.
31. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42: 200-13.
32. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
33. Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Kokkinos J, Kostrzema B, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995; 38: 119-24.
34. Joven B, Mellor-Pita S, D'Cruz D, Sharief M, Khamashita M, Hughes GR. Cerebral embolism complicating Libman-Sacks endocarditis-full recovery using recombinant tissue plasminogen activator. J Rheumatol 2002; 29: 2022-4.
35. Chaves CJ. Stroke in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome. Curr Treat Options Cardiovasc Med 2004; 6: 223-9.
36. Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, et al. Central nervous system involvement in systemic lupus erythematosus: Cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 2000; 9: 573-83.
37. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts; in the population-based Rotterdam Scan study. Stroke 2003; 34: 392-6.
38. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2023; 348: 1215-22.
39. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: Do they represent a new nosological entity? Ann Neurol 1998; 44: 629-34.
40. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GRV. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79: 57-68.
41. Harris EN, Gharavi AE, Mackworth-Young CG, Patel BM, Derue G, Hughes GR. Lupoid sclerosis: A possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985; 44: 281-3.
42. Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: A manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990; 17: 34-7.
43. Ruiz-Arguelles GJ, Guzman-Ramos J, Flores-Flores J, Garay-Martinez J. Refractory hiccough heralding transverse myelitis in the primary antiphospholipid syndrome. Lupus 1998; 7: 49-50.
44. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59: 120-4.
45. D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: Good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31: 280-5
46. Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment J Neurol 1995; 242: 326-31
47. Khamashta A, Gil A, Anciones B, Lavilla P, Valencia ME, Pintado V, et al. Chorea in systemic lupus erythematosus: Association with antiphospholipid antibodies. Ann Rheum Dis 1988; 47: 681-3
48. Asherson RA, Derksen RH, Harris EN, Bouma BN, Gharavi AE, Kater L, et al. Chorea in systemic lupus erythematosus and "lupus-like" disease: Association with antiphospholipid antibodies. Semin Arthritis Rheum 1987; 16: 253-9.
49. Asherson RA, Hughes GR. Antiphospholipid antibodies and chorea. J Rheumatol 1988; 15: 377-9.
50. Cervera, R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76: 203-12.
51. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 568-71.
52. Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: A literature investigation. Rheumatology (Oxford) 2002; 41: 605-18.
53. Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: The evidence and the myth. Brain 2004; 127: 1200-9.
54. Cuadrado MJ, Sanna G. Headache and systemic lupus erythematosus. Lupus 2003; 12: 943-6.
55. Brandt KD, Lessell S. Migrainous phenomena in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 7-16.
56. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140-7.
57. Cuadrado MJ, Khamashta MA, Hughes GR. Sticky blood and headache. Lupus 2001; 10: 392-3.
58. Hughes G, Cuadrado M, Khamashta M, Sanna G. Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome. Lupus 2001; 10: 778.
59. Cuadrado MJ, Sanna G, Sharief M, Khamashta MA, Hughes GRV. Double blind, crossover, randomised trial comparing low molecular weight heparin versus placebo in the treatment of chronic headache in patients with antiphospholipis antibodies. Arthritis Rheum 2003; 48: S364 (abstract).
60. Baca V, Lavalle C, Garcia R, Catalan T, Sauceda JM, Sanchez G, et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26: 432-9.
61. Wolkowitz OM, Reus VI, Weingartner H, Thompson K, Breier A, Doran A, et al. Cognitive effects of corticosteroids. Am J Psychiatry 1990; 147: 1297-303.
62. Wolkowitz OM, Reus VI, Canick J, Levin B, Lupien S. Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann N Y Acad Sci 1997; 823: 81-96.
63. Liu FY, Huang WS, Kao CH, Yen RF, Wang JJ, Ho ST. Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus crythematosus with brain involvement a preliminary report. Rheumatol Int 2003; 23: 182-5.
64. Sun SS, Huang WS, Chen JJ, Chang CP, Kan CH, Wang JJ. Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus crythematosus with brain involvement by Tc-99m HMPAO brain SPECT. Eur Radiol 2004; 14: 1311-5.
65. Quintero-Del-Rio AI, Van M. Neurologic symptoms in children with systemic lupus erythematosus. J Child Neurol 2000; 15: 803-7.
66. Funduchi M, Ohno M, Nozaki Y, Sugiyama M, Kinoshita K, Kanamura, A. Intrathecal corticosteroids for systemic lupus erythematosus with central nervous system involvement. J Rheumatol 2003; 30: 207-8.
67. Propper DJ, Bucknall RC. Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 512-5.
68. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Below JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81: 975-84.
69. Lee T, von Scheven E, Sandbo C. Systemic lupus erythematosus and antiphospholipid syndrom; in children and adolescents. Curr Opin Rheumatol 2001; 13: 415-21.
70. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosplhamide in the treatment of severe neuro-psychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
71. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-61.
72. Sakic B, Kolb B, Whishaw IQ, Gorny G, Szechtman H, Denburg JA. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J Neuroimmunol 2000; 111: 931-101.
73. Farrell M, Sakic B, Szechtman H, Denburg JA. Effect of cyclo-phosphamide on leukocytic infiltration in the brain of MRL/1pr mice. Lupus 1997; 6: 268-74.
74. Sakic B, Szechtman H, Denburg SD, Denburg JA. Immunosuppressive treatment prevents behavioral deficit in autouimmune MRL-1pr mice. Physiol Behav 1995; 58: 797-802.
75. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus-the effect of IV pulse methylprednisolone and cyclcphosphamide. J Rheumatol 1992; 19: 370-2.
76. Sanna G, Khamashta MA. Low-dose pulse cyclophosphamide in the treatment of neuropsychiattic lupus. Lupus 2003; 12: 1-2.
77. Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004; 23: 395-9.
78. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 166-73.
79. Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GR. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clip Exp Rheumatol 1996; 14: 295-9.
80. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1991; 56: 481-7.
81. Stajanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favorabl response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12: 3-7.
82. Schroeder JO, Euler HH. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol 1989; 260: 203-13.
83. Euler HH, Schroeder JO, Harten P, Zenner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37: 1784-94.
84. Gokhale YA, Bhide S, Rajadbyaksha S, Bichile LS, Hase NK. Plasmapheresis: An adjunct therapy in severe progressive neuropsychiatric lupus. J Assoc Physicians India 2001; 49: 986-9.
85. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003; 7: 173-82.
86. Perisse D, Amoura Z, Cohen D, Saintigny P, Mekhloufi F, Mazet P, et al. Case study: Effectiveness of plasma exchange in an adolescent with systemic lupus erythematosus and catatonia. J Am Acad Child Adolesc Psychiatry 2003; 42: 497-9.
87. Wright EC, Tullus K, Dillon MJ. Retrospective study of plasma exchange in children with systemic lupus erythematosus. Pediatr Nephrol 2004; 19: 1108-14.
88. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
89. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2001: CD002063.
90. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71-5.
91. Levy Y, Sherer Y, George J, Rovensky J, Lukac J, Rauova L, et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000; 29: 321-7.
92. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999; 8: 705-12
93. Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999; 18: 170-3.
94. Tomer Y, Shoenfield Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391-3.
95. Milstone A, Fan A. Fuchs H. Antiphospholipid syndrome associated with seizures. South Med J 1996; 89: 738-40.
96. Kwong KL, Chu R, Wong SN. Parkinsonism as unusual neurological complication in childhood systemic lupus erythematosus. Lupus 2000; 9: 474-7.
97. Valesini G, Priori R, Francia A, Balestrieri G, Tincani A, Airo P, et al. Central nervous system involvement in systemic lupus erythematosus: A new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994; 16: 313-21.
98. Dong Y, Zhang Y. Tang F, Tian X, Zhao Y, Zhang F. Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J (Engl) 2001; 114: 764-6.
99. Hay EM. Psychiatric disorder and cognitive impairment in SLE. Lupus 1994; 3: 145-8.
100. Schantz V, Oestargaard LL, Junker P. Shrinking spinal cord following transverse myelopathy in a patient with systemic lupus erythematosus and the phospholipid antibody syndrome. J Rheumatol 1998; 25: 1425-8.
101. Yazawa, S, Kawasaki S, Ohi T, Shiomi K, Sugimoto S, Kawagoe J, et al. Development of severe longitudinal atrophy of thoracic spinal cord following lupus-related myelitis. Intern Med 2001; 40: 353-7.
102. Grisanti M, Nader A, Cacciuttolo R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate mofetil. Lupus 2001; 10: S31.
103. Lhotta K, Wurzner R, Rosenkranz AP, Beer R, Rudisch A, Neumair F, et al. Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus 2004; 13:139-41.
104. Mathieu A, Sanna G, Mameli A, Pinna C, Vacca A, Cauli A, et al. Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuopsychiatric systemic lupus erythematosus. Lupus 2002; 11; 52-6.
105. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-8.
106. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 20Q2; 46: 2673-7.
107. Saito K, Nawata K Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12: 798-800.
108. Weide R, Heymanns J, Pandorf A. Kopplar H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12: 779-82.
109. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 67: 470-5.
110. Eren M, Baskin E, Cila A, Ozen S. Mannitol treatment in central nervous system lupus. Clin Rheumatol 2001; 20: 160-1.
111. Wallace DJ, Silverman S, Goldstein J, Hughes D. Use of hyperbaric oxygen in rheumatic diseases: Case report and critical analysis. Lupus 1995; 4: 172-5.
112. Giembycz MA, Smith SJ. Phosphodiesterase 7A: A new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 2006; 12(25): 3207-20.
113. Guglielmi L, Guglielmi P, Demoly P. Drug hypersensitivity: Epidemiology and risk factors. Curr Pharm Des 2006; 12(26): 3309-12.
114. Treka J, Kunz M. Functional genome and proteome analyses of cutaneous autoimmune diseases. Curr Pharm Des 2006; 12(29): 3787-98.